Novartis stock steadies after pause of autoimmune cell therapy trials
Published on 09/01/2026 at 08:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis (ISIN CH0012005267) stock is reacting to news on September 1, 2026 that the Swiss pharma group has halted multiple autoimmune cell therapy trials after reports of patient deaths, as investors gauge the potential impact on its innovation pipeline and long-term growth outlook. Recent market data show the ADR last closed at $152.46, giving the company a large-cap valuation in global healthcare benchmarks.
Trials paused after safety signal in autoimmune cell therapy
According to recent reporting on September 1, 2026, Novartis has suspended eight clinical studies of an autoimmune cell therapy program following fatal events among participants. One market report on the news highlighted that the company is pausing the immunology-focused cell therapy trials while it works with regulators and investigators to clarify the safety profile and assess next steps for the program.
The affected studies are part of Novartis's broader push into next-generation cell therapies beyond oncology, targeting diseases in immunology where long-term efficacy and safety requirements are particularly demanding. By acting at this stage of development, management aims to contain potential risk to patients and to the regulatory path, even if it temporarily slows a high-profile part of the pipeline.
Stock trades in a tight range after latest headlines
In US trading, the Novartis ADR recently closed at $152.46 on the latest completed session in late August 2026, with the quote used in several market reports as of September 1, 2026. European data show that in the home market on the SIX exchange the share was quoted at 124.14 CHF on August 31, 2026 after an intraday gain of 0.3 percent, while the stock opened that session at 124.00 CHF, indicating only modest day-to-day volatility.
For longer-term holders, performance over the past year has been favorable: one performance overview notes that a hypothetical Novartis position established one year earlier would have been worth 12,232.11 CHF on August 28, 2026, based on a closing price of 123.74 CHF, underscoring that total return has been supported by both price appreciation and dividends over that horizon. Taken together, these figures suggest that the current safety-related headlines are arriving against a backdrop of a stock that has already delivered solid one-year gains.
Recent earnings context and growth profile
While the safety pause has drawn attention, the operational backdrop is defined by the most recent earnings cycle, where Novartis reported higher revenue and profit for its latest quarter relative to the prior year period, driven by growth in key cardiovascular, oncology, and immunology products. In that report for the first half of 2026, management highlighted that innovative medicines remained the main growth engine, with double-digit expansion in selected brands helping to offset generic erosion elsewhere in the portfolio.
The same set of results showed that net income for the most recently reported half-year increased versus the comparable period a year earlier, reflecting both higher sales and ongoing efficiency measures. Management also reiterated full-year 2026 guidance that points to continued sales and core operating income growth versus 2025, underlining confidence that the broader business can absorb isolated pipeline setbacks while still expanding margins over time.
How the safety pause fits into the broader pipeline
From an investor perspective, the key question is how the cessation of eight autoimmune cell therapy studies changes the risk-reward balance of the late-stage pipeline. The affected portfolio sits alongside other advanced programs in areas such as oncology and cardiovascular disease, so the commercial impact will depend on whether the safety signal is specific to this program or suggests broader platform issues.
If the safety concerns remain confined to these particular studies and can be resolved by protocol changes or patient selection criteria, the financial impact could stay limited compared with the company’s diversified earnings base. Conversely, if watchdogs or internal reviews determine that the risk cannot be mitigated, Novartis would likely shift capital and R&D effort toward other mechanisms, potentially trimming longer-term revenue expectations for autoimmune cell therapies but preserving its innovation budget for adjacent opportunities.
Key product spotlight: Entresto as a growth driver
A central pillar of Novartis's current growth story is Entresto, its heart failure drug that has become one of the company’s top-selling products in recent years. In the latest half-year update, management reported that Entresto delivered year-over-year sales growth in the high-single-digit to low-double-digit range, supported by wider guideline inclusion and increasing penetration in both North America and Europe.
This trajectory has made Entresto an important offset to revenue lost from older drugs facing generic competition, helping to stabilize the overall cardiovascular franchise. For many investors, the continued expansion of Entresto, together with other key brands, provides a buffer against pipeline-specific disappointments such as the autoimmune cell therapy pause announced on September 1, 2026.
Novartis stock and valuation snapshot
With the ADR last quoted at $152.46 as of the most recently completed session referenced in early September 2026 and the Swiss line at 123.74 CHF at the close on August 28, 2026, Novartis currently trades close to the upper end of its 12-month range cited in recent performance reviews. The one-year gain implied by the 12,232.11 CHF portfolio value for an investment made a year earlier points to double-digit percentage appreciation over that span, even before considering dividends.
Based on recent market capitalization data for late August 2026, these prices translate into a valuation in the tens of billions of US dollars for Novartis, placing it among the larger global pharmaceutical groups by equity value. For US-based investors in the ADR, this scale, combined with a diversified portfolio and a consistent dividend, remains a central part of the investment narrative, even as specific pipeline events like the autoimmune trial pause add short-term uncertainty and headline risk.
Read more
More on Novartis stock in the company investor relations overview
Heart failure therapy underscores commercial strength
Entresto, indicated for certain forms of chronic heart failure, exemplifies how Novartis converts R&D investment into durable revenue streams. The drug has secured guideline support in major markets and has steadily expanded its eligible patient population as new clinical data have accumulated, which has underpinned its consistently rising contribution to group sales through the first half of 2026.
In addition, the company continues to invest in life-cycle management for Entresto, including studies in broader patient segments and real-world evidence programs designed to convince payers and physicians of its long-term benefit-risk profile. This kind of commercially validated asset provides a counterweight to the more experimental projects affected by the autoimmune cell therapy trial suspensions, illustrating why the overall earnings outlook for 2026 remains intact despite the latest safety setback.
Shares hold gains despite trial headwinds
Against this backdrop, Novartis shares have held much of their prior-year gains, with the Swiss line closing at 123.74 CHF on August 28, 2026 and then trading slightly higher at 124.14 CHF by the morning of August 31, 2026, an intraday increase of 0.3 percent. This pattern suggests that, so far, the market views the autoimmune study pause as manageable within the context of the company’s diversified revenue base and robust late-stage pipeline.
For investors following Novartis stock as of the start of September 2026, the combination of a strong existing product portfolio, including leading drugs such as Entresto, and the temporary setback in autoimmune cell therapy trials frames the near-term risk-reward balance. The shares last traded at $152.46 for the ADR in the latest referenced session, and future performance will depend on how quickly management can clarify the safety findings, reorient the pipeline where needed, and continue executing on its 2026 growth guidance.
Fact box
Company: Novartis AG
ISIN: CH0012005267
Ticker: NVS
Exchange: SIX Swiss Exchange / NYSE ADR
Price reference (ADR, last close as of late August 2026): $152.46 USD
Price reference (Swiss line, close as of August 28, 2026): 123.74 CHF
Market cap: large-cap global pharmaceutical group (as of late August 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Index membership: SMI (Swiss Market Index) and major global pharma benchmarks
